Neoadjuvant, Pancreatic Cancer
Conditions
Brief summary
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Detailed description
The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.
Interventions
DRUGNeoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Sponsors
Seoul National University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC) * Between January 2007 and June 2021 at Seoul National University Hospital
Exclusion criteria
* Patients who had borderline resectable PDAC with arterial invasion * Patients who received chemotherapy as initial treatment and did not undergo surgery * Incomplete follow-up data for analysis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months | the time from diagnosis to death from any cause or the date of the last visit |
Outcome results
None listed